Full-year revenue from operations up 9% to Rs 3,489 Cr, PAT1 up 12% to Rs 519 Cr Fourth quarter revenue from operations declined 8% year-on-year to Rs. 917 Cr, PAT1 increased 6% to Rs. 189 Cr Syngene International Limited today announced its full-year
Company reports resilient performance in the nine months to date: revenue from operations up 17% to Rs 2,572 crores, PAT up 16% to Rs 330 crores (before exceptional items) Syngene International Limited today announced its third quarter financial results. Reported revenue from operations for the quarter
Revenue from operations up 18.5% to Rs 910 crores, PAT (before exceptional items) up 20% to Rs 122 crores First half FY24 revenue from operations was up 22% to Rs 1,718 crores; Profit after tax (before exceptional items) up 23% to Rs 215 crores Syngene International Limited
Syngene (or the “Company”) today announced the acquisition of Unit 3 biologics manufacturing facility in Bangalore, India, from Stelis Biopharma Limited (SBL). The companies have entered into a binding term sheet and, on completion of the transaction, the site will add 20,000 liters of installed
